Assignee
KALOBIOS PHARMACEUTICALS INC
US·6 granted patents·15 pending applications·52 citations·filing 2002–2016
Top patents by PatentIndex Score
21 records- 0193US7981843B2Antibody specificity transfer using minimal essential binding determinantsKALOBIOS PHARMACEUTICALS INC·Filed 2005·Granted Jul 19, 2011·36 cites·14 claims
- 0270US7432063B2Methods for affinity maturationKALOBIOS PHARMACEUTICALS INC·Filed 2003·Granted Oct 7, 2008·11 cites·26 claims
- 0367US2015030614A1Antibodies to the pcrv antigen of pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0465US8044181B2Antibodies to the PcrV antigen of Pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2008·Granted Oct 25, 2011·0 cites·15 claims
- 0562US7335478B2Reactivation-based molecular interaction sensorsKALOBIOS PHARMACEUTICALS INC·Filed 2002·Granted Feb 26, 2008·5 cites·29 claims
- 0660US2014370010A1Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3KALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0759US2009181020A1Methods of Treating Bone-Loss Disorders Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0856US9290571B2Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2013·Granted Mar 22, 2016·0 cites·20 claims
- 0956US2008206241A1Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1054US8354251B2Transactivation system for mammalian cellsKALOBIOS PHARMACEUTICALS INC·Filed 2004·Granted Jan 15, 2013·0 cites·2 claims
- 1154US2017226227A1Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1251US2013156759A1Methods of treating dementia using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1351US2015329647A1Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone MarrowKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1449US2008171038A1Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1546US2015344565A1Antibodies to granulocyte-macrophage colony-stimulating factorKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1644US2017335001A1Detection of EphA3 as a Marker of the Presence of a Solid TumorKALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1743US2013109586A1Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acidKALOBIOS PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1842US2011245100A1Generation of antibodies to an epitope of interestKALOBIOS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 1942US2015246121A1Methods of treating chronic inflammatory diseases using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2037US2011243934A1Epha3 antibodies for the treatment of multiple myelomaKALOBIOS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 2133US2010272736A1Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infectionKALOBIOS PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →